Cartesian Therapeutics, Inc. — Director's Dealing 2026

Jan 2, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2025-12-30

Reporting Person: English Emily (Chief Operations Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-30	Common Stock	M	7500	$3.30	Acquired	70226	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-12-30	Stock Option (Right to Buy)	$3.30	M	7500	Disposed	2031-04-25	Common Stock (7500)	Direct

Footnotes

F1: These options are currently fully vested and exercisable.

F2: On November 13, 2023, the issuer acquired the Delaware corporation which was then-known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the issuer's common stock in connection with the merger.